All To Play For: CAR-T Specialist Celyad’s Big Year
Executive Summary
Celyad’s leadership team talks to Scrip about the critical nature of the coming months for its lead cancer therapy product, and CAR-T market differentiation.
You may also be interested in...
ASH First Look: CAR-T Therapies Against BCMA, CD19 And More
CAR-T therapies from Janssen, Celgene and others will get a lot of attention at the annual hematology meeting, including candidates with novel constructs and targets.
AML Paradigm Shift: Doctors Welcome Many New Approvals And Approaches
This year's ASH meeting reflected a peak of development success, with many new approvals and many more in the pipeline.
Investment And Acquisition In Rare Diseases
In Vivo talks to investors, analysts and companies in rare disease about the challenges they face to innovate and to grow.